SCHEMBL21069632

SCHEMBL21069632

CN(C[C@@H]1CN(C(=O)O)CCO1)C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 6/20 0.43
▸ CTSD P07339 2/20 0.39
▸ CTSL P07711 2/20 0.39
▸ CTSB P07858 2/20 0.39
▸ CTSS P25774 2/20 0.39
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NR1H4 Q96RI1 1/20 0.36
▸ RECQL P46063 1/20 0.33
▸ EPHA2 P29317 2/20 0.33
▸ HSD11B1 P28845 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ ERBB2 P04626 1/20 0.31
▸ EPHB4 P54760 1/20 0.31
▸ USP30 Q70CQ3 1/20 0.31
▸ SCN9A Q15858 1/20 0.31
▸ ASGR1 P07306 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29077496 1.00 PDK1 (0.43) PDK1CTSDCTSLCTSBCTSS
SCHEMBL21071431 1.00 PDK1 (0.43) PDK1CTSDCTSLCTSBCTSS
SCHEMBL29612770 0.81 MEN1 (0.48) PDK1SMN1; SMN2NR1H4HSD11B1HTR2C
SCHEMBL24571602 0.81 MEN1 (0.48) PDK1SMN1; SMN2NR1H4HSD11B1HTR2C
SCHEMBL29304057 0.81 MEN1 (0.48) PDK1SMN1; SMN2NR1H4HSD11B1HTR2C
SCHEMBL21070566 0.79 PDK1 (0.33) PDK1CTSDCTSLCTSBCTSS
SCHEMBL28506422 0.79 PDK1 (0.45) PDK1SCN9A
SCHEMBL18125939 0.79 PDK1 (0.45) PDK1SCN9A
SCHEMBL21071408 0.78 BCHE (0.39) PDK1CTSDCTSLCTSBCTSS
SCHEMBL21069432 0.78 BCHE (0.39) PDK1CTSDCTSLCTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
EP-3731869-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-11-04 — — EP disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PDK1 504/4885CTSD 817/4885CTSL 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback